Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In a large phase 3 obesity trial (ACHIEVE-1), orforglipron at daily doses of 3, 12 and 36 mg caused approximately: Diarrhoea: 1926% of participants (vs 9% on placebo) Nausea: 1318% (vs 2% on placebo) Constipation: 817% (vs 4% on placebo) Vomiting: 514% (vs 1% on placebo) Across multiple studies, 617% of people stopped treatment because of side effects, mostly gut-related symptoms
Long-Term Outcomes: While existing trials show robust weight loss over ~64 weeks, real-world effectiveness and durability of oral semaglutide for weight management will require ongoing observation
And that's when I texted my friend Martina Raskova, whos a nutrition coach: Im gonna fu*king do it
This is a question some patients taking tirzepatide have raised, particularly when experiencing new or unexplained symptoms during treatment
US$ 23.73
US$ 21.19
US$ 20.97
US$ 23.26
US$ 27.39
